Pila Pharma Q4’21: Approaching the Next Step - Redeye
Redeye leaves its comment on Pila Pharma following the announcement of its year-end report. The figures in the report were largely in line with our expectations, and we make no major amendments to our forecasts following today’s announcement.
ANNONS
Redeye leaves its comment on Pila Pharma following the announcement of its year-end report. The figures in the report were largely in line with our expectations, and we make no major amendments to our forecasts following today’s announcement.
